Acute pancreatitis with long-term celecoxib vs. ibuprofen or naproxen: data from the PRECISION trial.

Am J Gastroenterol

University of Melbourne Department of Medicine, Austin Health, Melbourne, Victoria, and Western Sydney University, Campbelltown, NSW, Australia. Baylor College of Medicine, Veterans Affairs Medical Center, Houston, TX, USA. Cleveland Clinic, Cleveland, OH, USA. Downstate College of Medicine, State University of New York, New York, NY, USA. Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Royal Brompton and Harefield Hospital Trust and Imperial College, London, United Kingdom. Pfizer, New York, NY, USA. Pfizer Ltd, Tadworth, UK.

Published: July 2018

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41395-018-0051-6DOI Listing

Publication Analysis

Top Keywords

acute pancreatitis
4
pancreatitis long-term
4
long-term celecoxib
4
celecoxib ibuprofen
4
ibuprofen naproxen
4
naproxen data
4
data precision
4
precision trial
4
acute
1
long-term
1

Similar Publications

20% acute pancreatitis (AP) develops into severe AP (SAP), a global health crisis, with an increased mortality rate to 30%-50%. Mitochondrial damage and immune disorders are direct factors, which exacerbate the occurrence and progression of AP. So far, mitochondrial and immunity injury in SAP remains largely elusive, with no established treatment options available.

View Article and Find Full Text PDF

Follicular lymphoma (FL) outcomes are heavily influenced by host immune activity with immune anti-tumor activity mitigated by PD-1/PD-L1 pathway engagement. Combination CD20-directed therapy plus PD-1 inhibition (PD-1i) increases T-cell tumor killing and NK-cell antibody-dependent cell cytotoxicity (ADCC). Mounting evidence supports immune-priming using PD-1i before cancer-directed agents.

View Article and Find Full Text PDF

Machine Learning-Guided Fluid Resuscitation for Acute Pancreatitis Improves Outcomes.

Clin Transl Gastroenterol

January 2025

Division of Gastroenterology, Department of Medicine.

Objectives: Ariel Dynamic Acute Pancreatitis Tracker (ADAPT) is an artificial intelligence tool using mathematical algorithms to predict severity and manage fluid resuscitation needs based on the physiologic parameters of individual patients. Our aim was to assess whether adherence to ADAPT fluid recommendations versus standard management impacted clinical outcomes in a large prospective cohort.

Method: We analyzed patients consecutively admitted to the Los Angeles General Medical Center between June 2015 to November 2022 whose course was richly characterized by capturing more than 100 clinical variables.

View Article and Find Full Text PDF

Background: Acute pancreatitis (AP) is a prevalent pathological condition of abdomen characterized by sudden onset, high incidence and complex progression. Timely assessment of AP severity is crucial for informing intervention decisions so as to delay deterioration and reduce mortality rates. Existing AP-related scoring systems can only assess current condition of patients and utilize only a single type of clinical data, which is of great limitation.

View Article and Find Full Text PDF

GLP-1 receptor agonists in diabetes and weight loss: the double-edged sword of innovation and risks.

Front Clin Diabetes Healthc

January 2025

School of Medicine, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (Promise), University of Palermo, Palermo, Italy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!